Mouse Study Links Statin Muscle Pain to a Skeletal Muscle Gene Mutation

Statin related muscle pain may depend partly on a patient’s biology, not simply on the medication. A preliminary 2025 study in the Journal of Clinical Investigation found that a mutation affecting skeletal muscle receptors made mice more prone to muscle symptoms after receiving simvastatin.

The result offers a possible explanation for statin associated muscle symptoms, or SAMS, which lead some patients to stop treatment. Up to 10% of people prescribed statins report muscle aches, although many take the drugs without difficulty. The study raises the prospect of identifying who may be at greater risk and, eventually, reducing symptoms. Its findings have so far been demonstrated only in mice.

How the mutation may trigger symptoms

Researchers compared genetically unmodified mice with mice carrying a mutation that affects skeletal muscle receptors. After simvastatin treatment, the mutated group was more likely to develop SAMS. The researchers linked the difference to changes in calcium release: with the mutation, statin exposure prompted excess calcium to enter muscle cells, which may produce pain or discomfort.

That mechanism could give clinicians a more specific way to discuss symptoms with patients, says Catherine Benziger, M.D., a member of the American College of Cardiology Prevention of Cardiovascular Diseases Council. She says research connecting a biological mechanism with clinical findings could help clarify why symptoms occur and who may be more susceptible.

Cheng-Han Chen, M.D., an interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center, sees another potential implication: a drug that targets the mutation might prevent symptoms. That possibility remains a research lead, not an available treatment.

Why the finding matters to statin treatment

Muscle symptoms are the most common reason patients discontinue statins, Chen says. Understanding their cause could help researchers develop ways to ease side effects and help more patients continue therapy.

That matters because statins remain an effective treatment for lowering LDL cholesterol and reducing the risk of heart attacks and strokes, Benziger says. For some patients, muscle aches or cramps are manageable; for others, symptoms are severe enough that a medication change is needed.

The new study doesn’t establish that the same mutation explains symptoms in people. Chen emphasizes that the findings come from a mouse model and need to be tested in humans. Until that work is done, the proposed calcium pathway offers a plausible explanation rather than a confirmed clinical cause.

What patients can discuss with a clinician

People taking or starting a statin should report muscle symptoms to their doctor rather than making treatment decisions on their own. Benziger says that when a patient develops muscle side effects, she may recommend stopping the statin for five to seven days to see whether symptoms resolve, then restarting it. If they return, she advises discussing a lower dose or a different statin with the clinician.

Some patients find that symptoms improve after switching to another statin, Chen says. If statins remain intolerable, cholesterol treatment still needs attention. Benziger stresses that reaching an LDL target is especially important for people with diabetes, kidney disease, prior heart disease, an elevated coronary artery calcium score, or other risk factors.

Clinicians may consider alternatives such as PCSK9 inhibitors or bempedoic acid. The appropriate choice depends on the individual and should be worked out with a doctor.

The next research step

The study points to a possible biological route behind SAMS and a potential target for future therapies. Benziger says that, if further research confirms the findings and shows they apply to people, they could inform treatments that reduce muscle symptoms or avoid this limitation.

For now, the practical takeaway is to raise symptoms with a clinician and keep cholesterol management on the agenda. Whether the mutation and calcium changes seen in mice translate into a useful way to predict or prevent muscle pain in people remains an open question.